Literature DB >> 19274441

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.

Feng Wang1, Scharri J Ezell, Yong Zhang, Wei Wang, Elizabeth R Rayburn, Dwayaja H Nadkarni, Srinivasan Murugesan, Sadanandan E Velu, Ruiwen Zhang.   

Abstract

We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19274441      PMCID： PMC6690195          DOI： 10.1007/s10637-009-9232-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  26 in total

Review 1.  Marine natural products as anticancer drugs.

Authors:  T Luke Simmons; Eric Andrianasolo; Kerry McPhail; Patricia Flatt; William H Gerwick
Journal:  Mol Cancer Ther       Date:  2005-02       Impact factor: 6.261

Review 2.  Marine natural products.

Authors:  John W Blunt; Brent R Copp; Murray H G Munro; Peter T Northcote; Michèle R Prinsep
Journal:  Nat Prod Rep       Date:  2006-01-09       Impact factor: 13.423

3.  Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.

Authors:  Zhuo Zhang; Hui Wang; Mao Li; Elizabeth R Rayburn; Sudhir Agrawal; Ruiwen Zhang
Journal:  Oncogene       Date:  2005-11-03       Impact factor: 9.867

4.  Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors.

Authors:  L R Barrows; D C Radisky; B R Copp; D S Swaffar; R A Kramer; R L Warters; C M Ireland
Journal:  Anticancer Drug Des       Date:  1993-10

5.  A new bastadin from the sponge Psammaplysilla purpurea.

Authors:  J R Carney; P J Scheuer; M Kelly-Borges
Journal:  J Nat Prod       Date:  1993-01       Impact factor: 4.050

Review 6.  Molecular markers of prostate cancer outcome.

Authors:  David I Quinn; Susan M Henshall; Robert L Sutherland
Journal:  Eur J Cancer       Date:  2005-04       Impact factor: 9.162

7.  Makaluvamine P, a new cytotoxic pyrroloiminoquinone from Zyzzya cf. fuliginosa.

Authors:  A Casapullo; A Cutignano; I Bruno; G Bifulco; C Debitus; L Gomez-Paloma; R Riccio
Journal:  J Nat Prod       Date:  2001-10       Impact factor: 4.050

Review 8.  Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer.

Authors:  Lucy L Seville; Nita Shah; Andrew D Westwell; Weng C Chan
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

Review 9.  The cell cycle: a review.

Authors:  K A Schafer
Journal:  Vet Pathol       Date:  1998-11       Impact factor: 2.221

10.  Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription.

Authors:  Sung Dae Cho; Cheng Jiang; Barbara Malewicz; Yan Dong; Charles Y F Young; Kyung-Sun Kang; Yong-Soon Lee; Clement Ip; Junxuan Lü
Journal:  Mol Cancer Ther       Date:  2004-05       Impact factor: 6.261
View more
  17 in total

1.  Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.

Authors:  Yong Zhang; Suk-Hyun Won; Cheng Jiang; Hyo-Jeong Lee; Soo-Jin Jeong; Eun-Ok Lee; Jinhui Zhang; Min Ye; Sung-Hoon Kim; Junxuan Lü
Journal:  Pharm Res       Date:  2012-01-27       Impact factor: 4.200

2.  Total synthesis of zyzzyanones A-D.

Authors:  Dwayaja H Nadkarni; Srinivasan Murugesan; Sadanandan E Velu
Journal:  Tetrahedron       Date:  2013-05-20       Impact factor: 2.457

3.  A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Yong Zhang; Jinhui Zhang; Lei Wang; Emily Quealy; Bernard D Gary; Robert C Reynolds; Gary A Piazza; Junxuan Lü
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

4.  Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes.

Authors:  Bing Xue; Wei Wang; Jiang-Jiang Qin; Bhavitavya Nijampatnam; Srinivasan Murugesan; Veronika Kozlovskaya; Ruiwen Zhang; Sadanandan E Velu; Eugenia Kharlampieva
Journal:  Acta Biomater       Date:  2017-06-03       Impact factor: 8.947

5.  Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.

Authors:  Yong Zhang; Kwan-Hyun Kim; Wei Zhang; Yinglu Guo; Sung-Hoon Kim; Junxuan Lü
Journal:  Int J Cancer       Date:  2011-05-09       Impact factor: 7.396

6.  Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Authors:  Scharri J Ezell; Haibo Li; Hongxia Xu; Xiangrong Zhang; Evrim Gurpinar; Xu Zhang; Elizabeth R Rayburn; Charnell I Sommers; Xinyi Yang; Sadanandan E Velu; Wei Wang; Ruiwen Zhang
Journal:  Mar Drugs       Date:  2010-07-13       Impact factor: 5.118

7.  A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Authors:  Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Deng Chen; Dwayaja H Nadkarni; Srinivasan Murugesan; Dongquan Chen; Ruiwen Zhang
Journal:  Breast Cancer Res Treat       Date:  2009-11-21       Impact factor: 4.872

8.  Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Authors:  Deng Chen; Wei Wang; Jiang-Jiang Qin; Ming-Hai Wang; Srinivasan Murugesan; Dwayaja H Nadkarni; Sadanandan E Velu; Hui Wang; Ruiwen Zhang
Journal:  Curr Cancer Drug Targets       Date:  2013-07       Impact factor: 3.428

9.  Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Authors:  Jun-Xian Yu; Sukesh Voruganti; Dan-Dan Li; Jiang-Jiang Qin; Subhasree Nag; Su Xu; Sadanandan E Velu; Wei Wang; Ruiwen Zhang
Journal:  Chin J Nat Med       Date:  2015-07

Review 10.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.